Late onset toxicities associated with the use of CDK 4/6 inhibitors in hormone receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer patients: a multidisciplinary, pan-EU position paper regarding their optimal management. The GIOCONDA project.

Cazzaniga, Marina Elena;Ciaccio, Antonio;Danesi, Romano;Duhoux, François;Snegovoy, Anton;et.al.
(2023) Frontiers in Oncology — Vol. 13, n° 1, p. 1247270 [1-10] (2023)

Files

fonc-13-1247270.pdf
  • Open Access
  • Adobe PDF
  • 2.2 MB
Download

Details

Authors
  • Cazzaniga, Marina Elena
    Author
  • Ciaccio, Antonio
    Author
  • Danesi, Romano
    Author
  • Duhoux, Françoisorcid-logoUCLouvain
    Author
  • Snegovoy, Anton
    Author
Show more
Abstract
The personalization of therapies in breast cancer has favoured the introduction of new molecular-targeted therapies into clinical practice. Among them, cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors have acquired increasing importance, with the approval in recent years of palbociclib, ribociclib, and abemaciclib in combination with endocrine therapy. Currently, no guidelines are available to monitor and manage potential long-term toxicities associated with the use of these drugs. A multidisciplinary panel of European oncologists, was supported by a pharmacologist, a hematologist, a hepatologist and a pulmonologist to discuss the management of long-term toxicities, based on the literature review and their clinical experience. The panel provided detailed roadmaps to manage long-term toxicities associated with the use of CDK4/6 inhibitors in clinical practice. Knowing the frequency and characteristics of the toxicity profile associated with each CDK4/6 inhibitor is important in the decision-making process to match the right drug to the right patient.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Cazzaniga, M. E., Ciaccio, A., Danesi, R., Duhoux, F., Girmenia, C., Zaman, K., Lindman, H., Luppi, F., Mavroudis, D., Paris, I., Olubukola, A., Samreen, A., Schem, C., Singer, C., & Snegovoy, A. (2023). Late onset toxicities associated with the use of CDK 4/6 inhibitors in hormone receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer patients: a multidisciplinary, pan-EU position paper regarding their optimal management. The GIOCONDA project. Frontiers in Oncology, 13(1), 1247270 [1-10]. https://doi.org/10.3389/fonc.2023.1247270 (Original work published 2023)